Diagnos Laboratorium Utama Tbk. vs Trimegah Karya Pratama Tbk. — how do they compare? Diagnos Laboratorium Utama Tbk. trades at Rp224 (market cap 308B, 27.5K 24h volume), while Trimegah Karya Pratama Tbk. trades at Rp140 (market cap 272.02B, 27.33M 24h volume). The key difference: Diagnos Laboratorium Utama Tbk. and Trimegah Karya Pratama Tbk. are close in size by market cap, and Trimegah Karya Pratama Tbk. is more actively traded (27.33M versus 27.5K). Which is the better fit depends on your goals.
| DGNS | UVCR | |
|---|---|---|
Market Cap | 308B | 272.02B |
Volume | 27.5K | 27.33M |
Lot | 275 | 273.33K |
Turnover | 6.23M | 3.79B |
Average Price | 226.59 | 138.72 |
Value | 6.23M | 3.79B |
Indicative Equilibrium Price | 230 | 137 |
Indicative Equilibrium Volume | 110 | 8.03K |
Trailing returns across standard periods
Latest headlines on both assets
PT Diagnos Laboratorium Utama Tbk (the “Company”) was established in the Republic of Indonesia on August 29, 2007 under framework of the Domestic Capital Investment Law No. 6 Year 1968 based on Deed No.17 dated August 29, 2007, of Martinef, S.H., M.Si., Notary in Bekasi. The Company started its commercial operation in 2008.
Read more on DGNS →PT Trimegah Karya Pratama Tbk (the Company) was established based on Notarial Deed No. 21 dated July 7, 2017 of Netty Maria Machdar, S.H. The Company started its commercial operations in 2018. The Company’s immediate parent company is PT Trimegah Sumber Mas, which was established and domiciled in Indonesia, while its ultimate Parent Company is PT Hutama Mulia Rajawali, which was established and domiciled in Indonesia.
Read more on UVCR →